* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download The macromolecular sites of action through which drugs
Ancestral sequence reconstruction wikipedia , lookup
Gene expression wikipedia , lookup
Magnesium transporter wikipedia , lookup
Expression vector wikipedia , lookup
Paracrine signalling wikipedia , lookup
G protein–coupled receptor wikipedia , lookup
Bimolecular fluorescence complementation wikipedia , lookup
Drug design wikipedia , lookup
Signal transduction wikipedia , lookup
Protein structure prediction wikipedia , lookup
Metalloprotein wikipedia , lookup
Nuclear magnetic resonance spectroscopy of proteins wikipedia , lookup
Clinical neurochemistry wikipedia , lookup
Interactome wikipedia , lookup
Western blot wikipedia , lookup
Protein purification wikipedia , lookup
Proteolysis wikipedia , lookup
Protein–protein interaction wikipedia , lookup
The macromolecular sites of action through which drugs mediate their effects are usually proteins. An understanding of what forces are responsible for the binding of drugs to proteins may be obtained by first considering what forces drive protein folding since these 2 processes share many common characteristics. The observed tertiary or quaternary structure of proteins is in large part a consequence of the hydrophobic effect. This means that proteins tend to bury hydrophobic residues in the core, while exposing hydrophilic residues to the exterior. Hydrophilic groups, if located at the interior are almost invariably paired with other hydrophilic groups to form hydrogen bonding interactions which compensate for the desolvation of these polar functions In this context, the ligand binding clefts in proteins often expose hydrophobic residues to solvent, and may contain partially desolvated hydrophilic groups that are not paired with complementary hydrogen bonding residues. These hydrophilic groups in this area are probably not exposed to sufficient solvent due to the steric constraints of protein folding. This means, that structurally, ligand binding pockets are sticky, representing non-optimally folded portions of the protein, and that such proteins may be considered as being incompletely folded. This also means that the interaction of a binding cleft with a complementary ligand is energetically favourable since this interaction buries exposed hydrophobic patches and forms favourable electrostatic contacts with hydrophilic groups that are located within the binding cleft and are insufficiently exposed to solvent. Hence, and very importantly, the association of the ligand with the protein may be viewed as the last step in the protein folding process. The stability of the protein is consequently increased consequent to ligand binding. From an evolutionary standpoint, endogenously, the stability of a protein is sacrificed in order to create a binding site, and this loss of stability may be recaptured by binding with an appropriate ligand. As with protein folding, the principal forces driving drug binding are thought to be the hydrophobic effect, and electrostatic interactions which include hydrogen bonding. It has been proposed furthermore, that the hydrophobic component, which is known to be largely nondirectional, contributes largely to affinity, whereas hydrogen bonding, because of its highly directional nature, contributes principally to specificity.